Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIMTA plus GEMZAR in pancreatic cancer
NCT00035035Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised trial of pemetrexed in pancreatic cancer (PC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Status: completed.
02
Drugs
pemetrexed
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00035035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035035.